The human and economic costs of undertreatment with statins

International Journal of Clinical Practice

Volumn 56, Issue 5, 2002, Pages 357-368

  Durrington, P ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PLACEBO; PRAVASTATIN; SIMVASTATIN;

CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIET THERAPY; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG USE; DYSLIPIDEMIA; ECONOMIC ASPECT; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH ECONOMICS; HUMAN; ISCHEMIC HEART DISEASE; MORBIDITY; MORTALITY; PATIENT ATTITUDE; PATIENT COMPLIANCE; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK FACTOR; SECONDARY PREVENTION; TREATMENT OUTCOME;

ANTILIPEMIC AGENTS; CHOLESTEROL, LDL; CORONARY DISEASE; COST-BENEFIT ANALYSIS; DRUG COSTS; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; HYPERLIPIDEMIAS; PATIENT COMPLIANCE; PRACTICE GUIDELINES; TREATMENT OUTCOME;

EID: 0036318858     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (90)

1. Health systems: Improving performance
2. The decline in ischemic heart disease mortality rates: An analysis of the comparative effects of medical interventions and changes in lifestyle
3. Trends in cardiovascular disease mortality in industrialized countries since 1950
4. International trends in coronary heart disease mortality, morbidity, and risk factors
5. Coronary heart disease statistics
6. Heart and stroke statistical update
7. Contribution of trends in survival and coronary-event rates to changes in coronary disease mortality: 10-year results from 37 WHO MONICA project populations: Monitoring trends and determinants in cardiovascular disease
8. International differences in coronary heart disease mortality and consumption of fish and other food-stuffs
9. Does diet or alcohol explain the French paradox?
10. Antioxidants in the Mediterranean diet
11. Wine consumption and other dietary variables in males under 60 before and after acute myocardial infarction
12. Pharmaco-economic aspects of lipid-lowering therapy: Is it worth the price?
13. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Sinivastatin Survival Study (4S)
14. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
15. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
16. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS
17. Pravastatin reduces total mortality in patients with coronary heart disease and average cholesterol levels: Relationship of baseline cholesterol and treatment effects in the LIPID trial
18. Systematic review on the risk and benefit of different cholesterol-lowering intervention
19. HDL-cholesterol and the treatment of coronary heart disease: Contrasting effects of atorvastatin and simivastatin
20. Prevention of coronary heart disease in clinical practice: Recommendations of the task force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension
21. Clinical reality of coronary prevention guidelines: A comparison of EUROASPIRE I and II in nine countries
22. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
23. A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial
24. The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease: Estimating the benefits of increasing HDL-C
25. Fluvastatin: A review of its use in lipid disorders
26. Atorvastatin
27. Cost-effectiveness of cholesterol lowering: Results from the Scandinavian Simvastatin Survival Study (4S)
28. Cost-effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease
29. Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease
30. Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease
31. Cost-effectiveness of lowering cholesterol with statins in patients with and without pre-existing coronary heart disease
32. Cost-effectiveness of statins
33. Comparative cost-effectiveness of HMG-CoA reductase inhibitors in secondary prevention of acute myocardial infarction
34. Cost-effectiveness of 3- hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the secondary prevention of cardiovascular disease: Forecasting the incremental benefits of preventing coronary and cerebrovascular events
35. Cost-effectiveness of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor therapy in older patients With myocardial infarction
36. Improving health outcomes without increasing costs: Maximising the full potential of lipid reduction therapy in the primary and secondary prevention of coronary heart disease
37. The pharmacoeconomic benefits of cholesterol reduction
38. Maximising the cost-effectiveness of lipid-lowering therapy
39. The cost of treating dyslipidaemia using National Cholesterol Education Program Guidelines
40. Economic aspects of hypercholesterolemia treatment with HMG-CoA reductase inhibitors: A review of recent developments
41. Cost-effectiveness of primary and secondary prevention in cardiovascular diseases
42. Pharmacoeconomics of lipid-lowering agents for primary and secondary prevention of coronary artery disease
43. Cost-effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment
44. Population benefits of cholesterol reduction: Epidemiology, economics and ethics
45. Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics
46. Choice of cost-effectiveness measure in the economic evaluation of cholesterol-modifying pharmacotherapy: An illustrative example focusing on the primary prevention of coronary heart disease in Canada
47. Cholesterol lowering and coronary heart dispase
48. Statin therapy, lipid levels, C-reactive protein and the survival of patients with angiographically severe coronary artery disease
49. Associations between change in C-reactive protein and serum lipids during statin treatment
50. At what coronary risk level is it cost-effective to initiate cholesterol-lowering drug treatment in primary prevention?
51. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel 111)
52. Effect of simvastatin treatment on cardiovascular resource utilization in impaired fasting glucose and diabetes. Findings from the Scandinavian Sinivastatin Survival Study
53. Clinical goals and performance measures for cholesterol management in secondary prevention of coronary heart disease
54. Time trends in the use of cholesterol-lowering agents in older adults
55. The treatment and prevention of coronary heart disease in Canada: Do older patients receive efficacious therapies? Clinical Quality Improvement Network (CQIN) Investigators
56. Prevention of coronary heart disease in clinical practice: Summary of recommendations of the Second Joint Task Force of European and other societies on coronary prevention
57. Second report of the expert panel on detection, evaluation, and treatment of high-blood cholesterol in adults (Adult Treatment Panel II)
58. Joint British recommendations on prevention of coronary heart disease in clinical practice: Summary
59. Coronary heart disease: National service frame-work
60. Comparative accuracy of cardiovascular risk prediction methods in primary care patients
61. Methods for the prediction of coronary heart disease risk
62. Recent trends in the identification and treatment of high blood cholesterol by physicians: Progress and missed opportunities
63. Rationale, design, and baseline results of the Pravastatin-to-Simvastatin Conversion Lipid Optimisation Program (PSCOP)
64. A European Society of Cardiology survey of secondary prevention of coronary heart disease: Principal results
65. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries: Principal results from EUROASPIRE II
66. Lipid management in patients at moderate risk for coronary heart disease: Insights from the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)
67. Prevention of coronary heart disease in clinical practice: A commentary on current treatment patterns in six European countries in relation to published recommendations
68. Growth in use of statins after trials is not targeted to most appropriate patients
69. Use of statins in general practices, 1996-8: Cross sectional study
70. LIPI-WATCH, a Belgian/Luxembourg Survey on Achievement of European Atherosclerosis Society lipid levels
71. The Lipid Treatment Assessment Project (L-TAP): Multicenter survey to evaluate the percentages of dyslipidaemic patients receiving lipid-lowering therapy and achieving NCEP target LDL-C goals
72. Treatment success in patient subgroups in the Lipid Treatment Assessment Project (L-TAP)
73. Prevention of coronary heart disease: Scientific background and new clinical guidelines
74. The undertreatment of LDL-cholesterol: Addressing the challenge
75. Treatment patterns and distribution of low-density lipoprotein cholesterol levels in treatment-eligible United States adults
76. Effectiveness of antihyperlipidemic drug management in clinical practice
77. The West of Scotland coronary prevention study: Economic benefit analysis of primary prevention with pravastatin
78. International economic analysis of primary prevention with pravastatin in WOSCOPs. The West of Scotland coronary prevention study
79. Economic implications of lipid-lowering trials: Current considerations in selecting a statin
80. A population-based treat-to-target pharmacoeconomic analysis of HMG-CoA reductase inhibitors in hypercholesterolaemia
81. The risk and cost-effective individual patient management: The challenge of a new generation of clinical trials
82. Double-masked comparison of the quality of life of hypercholesterolaemic men treated with simvastatin or pravastatin
83. General practitioner perceptions of treatment benefits and costs in patients with hypeflipidaemia
84. Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia
85. Enhancing drug compliance in lipid-lowering treatment
86. The problem of compliance to cholesterol altering therapy
87. Reassessing European Attitudes about Cardiovascular Treatment (REACT): Physicians survey